naproxen ER / Generic mfg. - LARVOL DELTA

Efficacy of JOINS Tablet for Lumbar Spinal Stenosis: Prospective, Randomized, Open-Label Clinical Trial. (PubMed, Medicina (Kaunas)) - "The control group was prescribed the usual spinal stenosis medications (Naproxen, Limaprost, and Pregabalin), while the test group was prescribed JOINS tablets in addition to the usual medications...At all follow-up periods, the functional outcomes did not show statistically significant differences between the test and control groups. The significant reduction in pain suggests that JOINS tablets may be an effective adjunct for pain relief, particularly in patients at high risk of adverse effects from long-term NSAID use."

Clinical • Journal • Back Pain • Inflammation • Lumbar Back Pain • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain

REB methodology application on topical and oral NSAIDS' therapeutic benefit evaluation on acute pain related to musculoskeletal injuries (PubMed, Therapie) - "According to REB methodology, topical NSAIDs, unlike oral formulations, have demonstrated efficacy in managing acute pain related to musculoskeletal injuries. These results reinforce recent meta-analyses favoring topical NSAIDs and recommending to limit the use of oral NSAIDs due to a lack of proof in this indication. Finally, NSAIDs impact on tissue healing has not been objectively studied by RCTs in humans, so further research is warranted. The use of NSAIDs in trauma care may potentially evolve as new data and knowledge emerge."

Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

Kidney Safety of Nonsteroidal Anti-Inflammatory Drugs in Patients with Arthritis: A Network Meta-Analysis (KIDNEY WEEK 2025) - "NSAIDs evaluated were naproxen (n=17,185), ibuprofen (n=28,531), celecoxib (n=37,843), oral diclofenac (n=6,060), rofecoxib (n=804), nabumetone (n=15), valdecoxib (n=544), and amtolmetin guacil (n=30)...Conclusion Rofecoxib, naproxen, and diclofenac are associated with a higher incidence of renal AEs, edema, and HTN compared with placebo, respectively. Physicians should weigh renal safety when prescribing NSAIDs for arthritis."

Retrospective data • Immunology • Osteoarthritis • Rheumatoid Arthritis • Rheumatology

Population Pharmacokinetics of Atogepant for the Prevention of Migraine. (PubMed, Clin Pharmacokinet) - P3 | "The pharmacokinetics of atogepant are similar in healthy participants and patients with CM or EM. Dose adjustments owing to intrinsic factors of age, sex, race, and body weight, or owing to concomitant medications consisting of P-glycoprotein (P-gp) inhibitors, BCRP inhibitors, oral contraceptive components (ethinyl estradiol and levonorgestrel), famotidine, esomeprazole, sumatriptan, acetaminophen, and naproxen are not necessary. Atogepant's popPK model provides a valuable tool for evaluating specific questions for patients, healthcare providers, and regulatory agencies. Integration into other modeling approaches has also aided in model-informed drug development decisions."

Journal • PK/PD data • Breast Cancer • CNS Disorders • Hepatology • Migraine • Oncology • Pain • Renal Disease • Solid Tumor

Patient-Reported Use of Concomitant Treatments for Crohn's Disease Among Adults Treated With Risankizumab in Clinical Practice: Initial Results From the ASPIRE-CD Study (ACG 2025) - "aCorticosteroids include oral prednisone, oral budesonide, and topical steroids.bOTC treatments include methylcellulose, loperamide, acetaminophen, ibuprofen, naproxen, vitamins, and mineral supplementation.cDietary adjustments include oral nutritional supplements and diet restriction (low fiber diet and low residual diet).Figure: Figure 2... Of the 286 patients who received the first induction RZB dose, 212 (76.0%) completed the wk20 survey. Most patients had prior biologic or Janus kinase inhibitor (JAKi) experience (75.2%) at baseline, with 45.5% having ≥ 2 prior biologics or JAKis. Patient-reported corticosteroid use reduced from 33.9% at baseline to 14.6% at wk20 (P < .001; Fig."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Gel-Phase Microextraction Using Microfluidic-Directed Ultrashort Peptide Assemblies for the Determination of Drugs in Oral Fluids. (PubMed, Int J Mol Sci) - "The peptide fibers co-assembled successfully with 5-fluorouracil (5-FU) and naproxen (39.8 ± 1.4 nmol of 5-FU and 27.4 ± 6.6 nmol of naproxen per 112 nmol of peptide used to prepare the fiber), resulting in a molar ratio drug/peptide ratio of approximately 1:3 and 1:4, respectively, demonstrating versatility in drug entrapment...The extension of the methodology to simulated saliva samples allowed extraction of 36% of 5-FU by the fiber, as determined by 19F NMR spectroscopy on microcoils, which enabled us to work with the small volume of fluid extracted from the microfluidic device and provided clean spectra and quantitative results. These findings highlight the potential of this tripeptide hydrogel as a sorbent material for therapeutic drug monitoring and toxicological analysis via a simple, non-invasive and rapid approach for drug detection in oral fluids."

Journal

A case of cutaneous vasculitis triggered by naproxen. (PubMed, Br J Nurs) - "Following assessment and investigations, naproxen was discontinued and oral prednisolone 40mg was prescribed...Nurses are central to recognising early skin changes, educating patients about potential adverse effects, and co-ordinating follow-up care. Effective communication and collaboration within the multidisciplinary team were crucial in achieving a positive outcome."

Journal • Musculoskeletal Pain • Pain • Vasculitis

SyrSpend® SF PH 4 as a Safe Vehicle for Extemporaneous Oral Suspensions: Microbiological Stability of Seven APIs. (PubMed, Int J Pharm Compd) - "This study aimed to evaluate the microbiological stability of oral suspensions containing dapsone, griseofulvin, levofloxacin, terbinafine, indometacin, naproxen, and paracetamol in SyrSpend® SF PH4, under both room temperature and refrigerated conditions...SyrSpend® SF PH4 effectively preserved the microbiological integrity of all tested formulations without added preservatives. These findings complement existing chemical stability data and support the use of SyrSpend® SF PH4 as a safe and effective vehicle for extemporaneous oral suspensions, particularly in populations requiring preservative-free formulations."

Journal

Stable Analgesia, Reduced Hepatic Burden: Pharmacokinetic and Pharmacodynamic Advantages of Transdermal Diclofenac Tape(ZICTHORU® Tape) in Personalized Oncology Care (ASA 2025) - "Oral NSAIDs such as naproxen and diclofenac undergo significant hepatic metabolism during the first-pass effect, potentially exacerbating existing liver dysfunction, particularly in patients receiving hepatotoxic anticancer therapies such as tyrosine kinase inhibitors and immunotherapy agents...G represents the period, including nighttime, during which the concentration remains above the dashed-line threshold when 225mg ZICTHORU® Tapes is applied once a day. These pharmacokinetic characteristics suggest that ZICTHORU®Tapes provides a more stable and sustained plasma concentration, potentially enhancing pain management while minimizing peak-related side effects."

PK/PD data • Hepatology • Liver Failure • Musculoskeletal Pain • Pain

Post-Thyroidectomy Complications Associated with NSAID Use (AAO-HNSF 2025) - "Two cohorts were created: those receiving opioid analgesics alone (OA) and those receiving opioid analgesics in combination with NSAIDs including ibuprofen, ketorolac, acetylsalicylic acid, naproxen, or celecoxib (ON), within two weeks post-thyroidectomy... NSAIDs are associated with slightly increased complications post-thyroidectomy. Further research is needed to explore the underlying mechanisms of this association."

Endocrine Disorders • Hematological Disorders • Infectious Disease • Otorhinolaryngology

Synthesis and biological evaluation of novel naproxen-phenacetin triazole hybrids as promising anti-inflammatory agents with enhanced gastrointestinal tolerability. (PubMed, Bioorg Chem) - "Compounds 46 (IC₅₀ = 0.16 μM, SI = 2.36), 55 (0.19 μM, SI = 2.27), and 59 (0.21 μM, SI = 1.65) demonstrated potency comparable to celecoxib...Orally administered compounds 55 and 64 (20 mg/kg) reduced paw oedema by 61 % and 52 %, respectively, similar to indomethacin (52 %), without causing visible gastric lesions (lesion score ∼ 2 vs. 5 for indomethacin)...Overall, the 1,2,4-triazole-thione-naproxen/phenacetin hybrids represent promising lead candidates for the development of GI-safer NSAIDs. Compounds 55 and 64, in particular, merit further optimization and long-term safety evaluation."

Journal

Comparative effects of cyclooxygenase-2 selective and nonselective nonsteroidal anti-inflammatory drugs and acetaminophen on rotator cuff tendon-bone healing in a rat model. (PubMed, Acta Orthop Traumatol Turc) - "Objective: This study aimed to investigate and compare the e!ects of naproxen (a nonselective nonsteroidal anti-inflammatory drug [NSAID]), celecoxib (a cyclooxygenase (COX)-2 selective NSAID), and acetaminophen (an analgesic with minimal anti-inflammatory activity) on tendon and tendon-bone healing following surgically induced supraspinatus tendon repair in a rat model...Although biomechanical di!erences were not statistically significant at 28 days, histological findings underscore the potential impact of analgesic selection on early postoperative tendon healing. Level of Evidence: N/A."

Clinical • Journal • Preclinical • Pain

The efficacy and safety of XG005, a novel non-opioid chemical entity concurrently inhibiting both nociceptive and neuropathic signals, in managing post-operative pain: a randomized, placebo-controlled phase 2b trial (PAINWeek 2025) - P2/3 | "XG005 is a single molecule conjugating naproxen and pregabalin, which is not active in gastrointestinal tract and thus minimizes naproxen side effects compared with administering naproxen directly...Qualified subjects were randomized (1:1:1) to receive either 1250 mg or 750 mg of XG005 tablets, or placebo...Tramadol consumption in the placebo group was 4.1- or 3.0-fold more than in the 1250 mg or 750 mg groups over 72 hours, and those were 3- or 2.5-fold in acetaminophen consumption...In comparison with other analgesics to treat acute pain using the same bunionectomy model with the same efficacy endpoint (SPI48) or Summed Pain Intensity Difference at 48 hours (SPID48), the pooled mean effect sizes are: 0.59 with various NSAIDs, 0.52 with various opioids combination with either acetaminophen or NSAIDs, 0.88 with tapentadol (an opioid) and 0.36 with a Nav1.8 antagonist... This trial randomized 450 participants (median age, 48 years; 80% female) with comparable..."

Clinical • P2b data • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain • Psychiatry • Sleep Disorder • NAV1

Effect of Mixing Technology on Homogeneity and Quality of Sodium Naproxen Tablets: Technological and Analytical Evaluation Using HPLC Method. (PubMed, Molecules) - "The analytical method proved fast and robust, allowing for reliable API quantification without full chromatographic separation. These findings underscore the need to balance mechanical blending energy with formulation properties and support the use of streamlined analytical strategies in pharmaceutical development."

Journal

Reduced opioids after total joint replacement surgery (REPAIRS): a pilot randomized controlled trial. (PubMed, J Orthop Surg Res) - P4 | "This pilot trial indicated that a full-scale trial would be feasible and acceptable. Such a trial could provide evidence of comparative effectiveness for the reduced opioid regimen in this population."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Musculoskeletal Diseases • Orthopedics • Pain

Comparative Effects of Naproxen, Diclofenac, and Piroxicam on Temporomandibular Disorders: A Clinical Trial. (PubMed, Front Dent) - "Materials and This clinical trial was conducted on 104 patients who were randomly assigned to four groups (n=26) to receive either 500mg naproxen tablets, 50mg diclofenac tablets, 10mg piroxicam capsules, or the placebo...The mean pain intensity and tenderness were significantly lower in the naproxen group than the other groups (P<0.05). Naproxen tablets can reduce pain and tenderness in TMD patients more than diclofenac tablets, piroxicam capsules, and the placebo."

Journal • Musculoskeletal Diseases • Pain • Rheumatology

Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study. (PubMed, Int J Clin Oncol) - "These findings suggest that celecoxib is less aggravating on CIN than non-selective COX inhibitors."

Clinical • Journal • Retrospective data • Anorexia • Lung Cancer • Oncology • Solid Tumor

Asthma and Anaphylaxis Induced by Milk with NSAID as a Cofactor in Adult Patient Sensitized to Dairy Proteins Due to Environmental Exposure in a Dairy Farm (EAACI 2025) - "A 43-year-old male, non-dairy worker, living adjacent to a dairy farm presented with episodes of severe anaphylaxis and worsenig asthma after ingesting milk-containing products, with the most severe reactions occurring when combined with naproxen use...He was treated with IM epinephrine, corticosteroids, and bronchodilators...Meloxicam was well tolerated...Moreover, NSAIDs should be carefully assessed as cofactors in food-induced anaphylaxis. OIT with milk helped to control asthma and anaphylaxis."

Clinical • Late-breaking abstract • Food Hypersensitivity • Immunology

Dose-dependent NSAID effects on autophagy and fibrosis pathways in renal tubular epithelial cells (ERA 2025) - "Cells were then treated with indomethacin (IND; 10, 20, 40 µg/mL), celecoxib (CEL; 0.72, 2.1, 4.3, 8.7 µg/mL), and naproxen (NAP; 15, 30, 60, 110 µg/mL) or DMSO (controls)... High doses of celecoxib and naproxen activated pro-fibrotic pathways while disrupting autophagic flux in renal proximal tubular cells. Our findings underscore the need for dose optimization of these medications especially in patients with kidney disease to avoid NSAID-induced nephrotoxicity."

Fibrosis • Immunology • Nephrology • Renal Disease • ACTA2 • EGR1 • MMP9 • SQSTM1 • TGFB1 • TIMP1

Curious case of unexplained renal dysfunction in a young male: clinicopathological correlation (UKKW 2025) - "5 years before that he presented to the different hospital and prior to presentation he had taken a prolonged course of Naproxen for acute onset traumatic back pain which eventually self-resolved...Genetic KIN is known to be associated with FAN 1 gene mutations, a genetic screen has therefore been undertaken and the result is pending. Conclusion Our case illustrates the importance of a kidney biopsy in patients with unexplained renal dysfunction even if the patient has confounding history such as NSAID intake to guide further focused investigations or appropriate prognostication."

Clinical • Back Pain • CNS Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Migraine • Mood Disorders • Musculoskeletal Pain • Nephrology • Pain • Psychiatry • Renal Disease • Vasculitis

Establishing virtual bioequivalence and bio-related dissolution specifications for naproxen using physiologically based pharmacokinetic modeling and in vitro biorelevant dissolution testing. (PubMed, Drug Dev Ind Pharm) - "Finally, extrapolation of the combined PBPK model to humans showed that drugs with different in vitro dissolution profiles are bioequivalent in humans. These findings will help demonstrate the biowaiver of naproxen tablets, which has implications for scale-up or post-approval changes in naproxen tablets."

Journal • PK/PD data • Preclinical

Impact of various electromagnetic fields on the transdermal permeability of naproxen and the effect of active compound exposure on magnetic field properties. (PubMed, Eur J Pharm Biopharm) - "This research highlights the potential of optimizing EMF parameters to enhance transdermal drug delivery and provides insights into the physicochemical interactions between EMFs and active compounds. The findings suggest that rotating magnetic fields, particularly at 50 Hz, offer the most significant improvement in drug permeability, which could be beneficial for developing advanced transdermal delivery systems."

Journal

Novel Treatment Approach That Avoids High-dose Oral Steroids in a Patient With Relapsing Polychondritis (ATS 2025) - "Subsequently, a naproxen taper was initiated, and she was transitioned to methotrexate (7.5 mg once weekly) with folic acid supplementation...In addition, for patients such as the one described in this case who have RPC with mild to moderate organ involvement, current treatment recommendations are to initiate prednisone (1 mg/kg daily) before transitioning to a second-line agent, such as methotrexate, with concomitant dose reduction or cessation of oral glucocorticoids. This case demonstrated that oral glucocorticoids are not always necessary to achieve symptomatic improvement and that an oral NSAID may be sufficient. In such instances, patients are spared from exposure to high-dose oral steroids and the associated potential adverse effects, including increased risk of infection, fractures, hypertension, hyperglycemia, and dyslipidemia."

Clinical • Cardiovascular • Cough • Diabetes • Dyslipidemia • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus Nephritis • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Ocular Inflammation • Orthopedics • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases

Chronic non-bacterial osteomyelitis in children- five-year standardized follow-up of a prospective observational cohort in the pre-biological era. (PubMed, Pediatr Rheumatol Online J) - "Most children experienced favourable long-term outcomes. Clinical improvement occurred more rapidly than radiologic resolution. Patients with insufficient response to NSAIDs should be considered for a treat-to-target approach, including the use of conventional and biologic DMARDs."

Journal • Observational data • Inflammation

Buccal application of microneedles coated with an optimized hydrogel containing naproxen and dexamethasone. (PubMed, Drug Deliv Transl Res) - "NDgel demonstrated concentration-dependent inhibition of nitrogen oxide (NO) production at 1-1000 µg/mL, and alkaline phosphatase (ALP) activity assays revealed a 1.2-fold increase at concentrations above 50 µg/mL. These findings suggest that hydrogel-coated MNs have potential as a novel drug delivery system for reducing inflammation and promoting osteocyte differentiation due to their enhanced permeability and bioactivity."

Journal • Dental Disorders • Inflammation • Periodontitis